
Maze Therapeutics, Inc.: shareholders and insiders
Price
$31.20
November 18, 2026Market cap $1.7B
What Ploutos Investor adds for Maze Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2025
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 4, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$25M
6 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan91%
- The rest9%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $19M by 6 people
- 2025: no buys, sold $5.4M by 3 people
- 2026: no buys, sold $19M by 6 people
- Nov 2, 2026Jason Coloma VChief Executive OfficerKind10b5-1
- Nov 2, 2026Jason Coloma VChief Executive OfficerKind10b5-1
- Nov 2, 2026Jason Coloma VChief Executive OfficerKind10b5-1
- Nov 2, 2026Jason Coloma VChief Executive OfficerKind10b5-1
- Oct 29, 2026Atul DandekarCSBOKind10b5-1
- Oct 29, 2026Atul DandekarCSBOKind10b5-1
- Oct 29, 2026Atul DandekarCSBOKind10b5-1
- Oct 1, 2026Jason Coloma VChief Executive OfficerKind10b5-1
- Oct 1, 2026Jason Coloma VChief Executive OfficerKind10b5-1
- Oct 1, 2026Harold BernsteinPresident, R&D & CMOKind10b5-1
- Oct 1, 2026Harold BernsteinPresident, R&D & CMOKind10b5-1
- Sep 29, 2026Atul DandekarCSBOKind10b5-1
- Sep 29, 2026Atul DandekarCSBOKind10b5-1
- Sep 4, 2026Harold BernsteinPresident, R&D & CMOKind10b5-1
- Sep 3, 2026Phillips CourtneyGC and Corp. SecretaryKind
- Sep 3, 2026Phillips CourtneyGC and Corp. SecretaryKind
- Sep 3, 2026Atul DandekarCSBOKind
- Sep 3, 2026Atul DandekarCSBOKind
- Sep 3, 2026Jason Coloma VChief Executive OfficerKind
- Sep 3, 2026Jason Coloma VChief Executive OfficerKind
- Sep 3, 2026Harold BernsteinPresident, R&D & CMOKind
- Sep 3, 2026Harold BernsteinPresident, R&D & CMOKind
- Sep 2, 2026Phillips CourtneyGC and Corp. SecretaryKind
- Sep 2, 2026Phillips CourtneyGC and Corp. SecretaryKind
- Sep 2, 2026Atul DandekarCSBOKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | Jason Coloma VChief Executive Officer | 10b5-1 | 2,257 | $30.12 | $68.0K | Form 4 |
| Nov 2, 2026 | Jason Coloma VChief Executive Officer | 10b5-1 | 336 | $30.91 | $10.4K | Form 4 |
| Nov 2, 2026 | Jason Coloma VChief Executive Officer | 10b5-1 | 26.6K | $30.10 | $799.4K | Form 4 |
| Nov 2, 2026 | Jason Coloma VChief Executive Officer | 10b5-1 | 5,345 | $31.05 | $166.0K | Form 4 |
| Oct 29, 2026 | Atul DandekarCSBO | 10b5-1 | 6,643 | $10.42 | $69.2K | Form 4 |
| Oct 29, 2026 | Atul DandekarCSBO | 10b5-1 | 857 | $10.42 | $8.9K | Form 4 |
| Oct 29, 2026 | Atul DandekarCSBO | 10b5-1 | 7,500 | $32.07 | $240.5K | Form 4 |
| Oct 1, 2026 | Jason Coloma VChief Executive Officer | 10b5-1 | 2,593 | $27.02 | $70.1K | Form 4 |
| Oct 1, 2026 | Jason Coloma VChief Executive Officer | 10b5-1 | 31.9K | $27.02 | $862.2K | Form 4 |
| Oct 1, 2026 | Harold BernsteinPresident, R&D & CMO | 10b5-1 | 16.1K | $10.42 | $168.2K | Form 4 |
| Oct 1, 2026 | Harold BernsteinPresident, R&D & CMO | 10b5-1 | 16.1K | $26.93 | $434.7K | Form 4 |
| Sep 29, 2026 | Atul DandekarCSBO | 10b5-1 | 7,500 | $10.42 | $78.2K | Form 4 |
| Sep 29, 2026 | Atul DandekarCSBO | 10b5-1 | 7,500 | $27.06 | $202.9K | Form 4 |
| Sep 4, 2026 | Harold BernsteinPresident, R&D & CMO | 10b5-1 | 9,705 | $26.22 | $254.5K | Form 4 |
| Sep 3, 2026 | Phillips CourtneyGC and Corp. Secretary | 1,990 | $26.01 | $51.8K | Form 4 | |
| Sep 3, 2026 | Phillips CourtneyGC and Corp. Secretary | 22 | $25.78 | $567 | Form 4 | |
| Sep 3, 2026 | Atul DandekarCSBO | 3,207 | $26.01 | $83.4K | Form 4 | |
| Sep 3, 2026 | Atul DandekarCSBO | 36 | $25.81 | $929 | Form 4 | |
| Sep 3, 2026 | Jason Coloma VChief Executive Officer | 11.3K | $26.01 | $293.5K | Form 4 | |
| Sep 3, 2026 | Jason Coloma VChief Executive Officer | 129 | $25.77 | $3.3K | Form 4 | |
| Sep 3, 2026 | Harold BernsteinPresident, R&D & CMO | 5,130 | $26.01 | $133.4K | Form 4 | |
| Sep 3, 2026 | Harold BernsteinPresident, R&D & CMO | 59 | $25.78 | $1.5K | Form 4 | |
| Sep 2, 2026 | Phillips CourtneyGC and Corp. Secretary | 1,738 | $26.38 | $45.8K | Form 4 | |
| Sep 2, 2026 | Phillips CourtneyGC and Corp. Secretary | 243 | $27.12 | $6.6K | Form 4 | |
| Sep 2, 2026 | Atul DandekarCSBO | 2,800 | $26.38 | $73.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by MAZE's officers and directors from 2025 up to November 18, 2025, 1 more calendar year
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 2 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- ARCH Venture Fund X, L.P.with 8 more personsShare of class9.40%
- Third Rock Ventures IV, L.P.with 5 more personsShare of class9.30%
- Deep Track Capital, LPwith 2 more personsShare of class9.02%
- Frazier Life Sciences Public Fund, L.P.with 9 more personsShare of class9.00%
- Janus Henderson GroupShare of class5.80%
- BlackRock, Inc.Share of class5.40%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| ARCH Venture Fund X, L.P.with 8 more persons | 9.40% | 4.12M | May 15, 2025 | 13G | |
| Third Rock Ventures IV, L.P.with 5 more persons | 9.30% | 4.47M | Feb 13, 20262 filings since May 9, 2025 | 13G/A | |
| Deep Track Capital, LPwith 2 more persons | 9.02% | 3.95M | Aug 14, 20252 filings since Feb 7, 2025 | 13G/A | |
| Frazier Life Sciences Public Fund, L.P.with 9 more persons | 9.00% | 4.34M | Feb 13, 20265 filings since Feb 10, 2025 | 13G/A | |
| Janus Henderson Group | 5.80% | 2.86M | May 15, 20264 filings since May 14, 2025 | 13G/A | |
| BlackRock, Inc. | 5.40% | 2.98M | Jul 29, 2026 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+85%
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter-0.7%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 1.58M | +85% | $43M | 0.02% |
| D.E. Shaw | – | – | 0.00% | |
| AQR Capital | 27.0K | -0.7% | $700.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 13.8% of its shares outstanding were held short, +14.7% since the report before.
- Shares held short
- 7.53M
- 13.8%
- Since the report before6.57M on Sep 30, 2026
- +14.7%
- 10.1
- 745.7K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 91%
- Report date
- Oct 15, 2026
- Shares held short
- Feb 14, 2025: Shares held short 1.20M
- Feb 28, 2025: Shares held short 1.68M
- Mar 14, 2025: Shares held short 1.84M
- Mar 31, 2025: Shares held short 2.68M
- Apr 15, 2025: Shares held short 2.18M
- Apr 30, 2025: Shares held short 2.18M
- May 15, 2025: Shares held short 2.03M
- May 30, 2025: Shares held short 1.90M
- Jun 13, 2025: Shares held short 2.15M
- Jun 30, 2025: Shares held short 2.02M
- Jul 15, 2025: Shares held short 1.94M
- Jul 31, 2025: Shares held short 1.55M
- Aug 15, 2025: Shares held short 1.78M
- Aug 29, 2025: Shares held short 1.73M
- Sep 15, 2025: Shares held short 1.63M
- Sep 30, 2025: Shares held short 2.46M
- Oct 15, 2025: Shares held short 2.31M
- Oct 31, 2025: Shares held short 2.36M
- Nov 14, 2025: Shares held short 2.44M
- Nov 28, 2025: Shares held short 2.22M
- Dec 15, 2025: Shares held short 2.22M
- Dec 31, 2025: Shares held short 2.61M
- Jan 15, 2026: Shares held short 2.58M
- Jan 30, 2026: Shares held short 2.74M
- Feb 13, 2026: Shares held short 3.36M
- Feb 27, 2026: Shares held short 3.44M
- Mar 13, 2026: Shares held short 3.59M
- Mar 31, 2026: Shares held short 3.89M
- Apr 15, 2026: Shares held short 3.80M
- Apr 30, 2026: Shares held short 4.35M
- May 15, 2026: Shares held short 3.95M
- May 29, 2026: Shares held short 3.90M
- Jun 15, 2026: Shares held short 4.06M
- Jun 30, 2026: Shares held short 5.53M
- Jul 15, 2026: Shares held short 5.53M
- Jul 31, 2026: Shares held short 5.68M
- Aug 14, 2026: Shares held short 5.99M
- Aug 31, 2026: Shares held short 5.92M
- Sep 15, 2026: Shares held short 5.68M
- Sep 30, 2026: Shares held short 6.57M
- Oct 15, 2026: Shares held short 7.53M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading62.6% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 62.6% of the shares in the reported trades were short sales, against 51.5% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 62.6%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 51.5%
- Change
- +11.1 pts
- Short sales a dayon average, of 253.7K shares
- 158.9K
- More than atof 3,656 US-listed companies, same days
- 88%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 38.6%
- Oct 13, 2026: Short sales 66.5%
- Oct 14, 2026: Short sales 57.7%
- Oct 15, 2026: Short sales 54.1%
- Oct 16, 2026: Short sales 53.7%
- Oct 19, 2026: Short sales 48.4%
- Oct 20, 2026: Short sales 46.8%
- Oct 21, 2026: Short sales 58.9%
- Oct 22, 2026: Short sales 52.6%
- Oct 23, 2026: Short sales 65.7%
- Oct 26, 2026: Short sales 57.2%
- Oct 27, 2026: Short sales 51.2%
- Oct 28, 2026: Short sales 52.8%
- Oct 29, 2026: Short sales 50.4%
- Oct 30, 2026: Short sales 62.4%
- Nov 2, 2026: Short sales 60%
- Nov 3, 2026: Short sales 62.8%
- Nov 4, 2026: Short sales 66.7%
- Nov 5, 2026: Short sales 64.3%
- Nov 6, 2026: Short sales 59.2%
- Nov 9, 2026: Short sales 50.2%
- Nov 10, 2026: Short sales 53.7%
- Nov 11, 2026: Short sales 44.7%
- Nov 12, 2026: Short sales 75%
- Nov 13, 2026: Short sales 79%
- Nov 16, 2026: Short sales 73.3%
- Nov 17, 2026: Short sales 47.7%
- Nov 18, 2026: Short sales 61.8%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Jason Coloma VChief Executive OfficerDirectly199.9K
- Atul DandekarCSBODirectly32.3K
- Amy BachrodtSVP, FinanceDirectly13.3K
- Phillips CourtneyGC and Corp. SecretaryDirectly7,007
- Harold BernsteinPresident, R&D & CMODirectly–
- Catherine A. SohnDirectorDirectly–
- Richard H SchellerDirectorDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Jason Coloma VChief Executive Officer | 199.9K | – | Nov 2, 2026 | Form 4 |
| Atul DandekarCSBO | 32.3K | – | Oct 29, 2026 | Form 4 |
| Amy BachrodtSVP, Finance | 13.3K | – | Apr 1, 2026 | Form 4 |
| Phillips CourtneyGC and Corp. Secretary | 7,007 | – | Sep 3, 2026 | Form 4 |
| Harold BernsteinPresident, R&D & CMO | – | – | Oct 1, 2026 | Form 4 |
| Catherine A. SohnDirector | – | – | Jan 7, 2026 | Form 4 |
| Richard H SchellerDirector | – | – | Sep 15, 2025 | Form 4 |
A lower bound: it counts only the 7 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.23%
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.19%
- IBBiShares Biotechnology ETFWeight in the fund0.08%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.05%
- IWMiShares Russell 2000 ETFWeight in the fund0.03%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.02%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.02%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
16 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 94
- Q4 2025: Managers 143
- Q1 2026: Managers 166
- Q2 2026: Managers 162
Institutional investors by quarter
The fund managers holding MAZE, quarter by quarter, from Q1 2025 to Q2 2025, 2 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 6 quarters.
Q2 2026: 162 managers held 58.53M shares, worth $1.7B. During the quarter 37 opened a position, 43 closed one, 64 added and 36 trimmed.
The largest holders, Q2 2026
- Frazier Life Sciences ManagementIn the quarter+10%
- Trv Gp IvIn the quarter
- ARCH Venture ManagementIn the quarter
- Deep Track CapitalIn the quarter+7.3%
- BlackRockIn the quarter+36%
- Jupiter TopcoIn the quarter
- T. Rowe Price Investment ManagementIn the quarter
- Logos Global ManagementIn the quarter+57%
- Vanguard Capital ManagementIn the quarter+24%
- a16z Capital ManagementIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Frazier Life Sciences Management | 5.03M | +10% | $150M |
| Trv Gp Iv | 4.47M | $134M | |
| ARCH Venture Management | 4.12M | $123M | |
| Deep Track Capital | 3.73M | +7.3% | $111M |
| BlackRock | 3.50M | +36% | $105M |
| Jupiter Topco | 3.41M | $102M | |
| T. Rowe Price Investment Management | 2.60M | $78M | |
| Logos Global Management | 1.94M | +57% | $58M |
| Vanguard Capital Management | 1.78M | +24% | $53M |
| a16z Capital Management | 1.70M | $51M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Maze Therapeutics's filings show?
Who buys and sells is one part of Maze Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have MAZE's insiders bought or sold?
From May 27, 2026 to Nov 4, 2026 Maze Therapeutics's insiders bought 0 and sold $11M of shares on the market. 90% of the sales were under set 10b5-1 plans.
Which well-known managers hold MAZE?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $43M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.